請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/22467完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 李水盛 | |
| dc.contributor.author | Yun-Ting Wang | en |
| dc.contributor.author | 王韻婷 | zh_TW |
| dc.date.accessioned | 2021-06-08T04:18:28Z | - |
| dc.date.copyright | 2010-09-13 | |
| dc.date.issued | 2010 | |
| dc.date.submitted | 2010-07-27 | |
| dc.identifier.citation | 1. http://www.diabetes.org/ (American Diabetes Association)
2. http://www.endo-dm.org.tw/dia/dia_default.asp(中華民國糖尿病學會) 3. Rathmann, W.; Giani, G., Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27, 2568-2569. 4. 行政院衛生署2005-2008國民營養健康狀況變遷調查 5. Michael, J.; Fowler, MD., Diabetes: Magnitude and Mechanisms. Clinical Diabetes 2010, 28, 42-46. 6. Curtis, R.; Geesaman B. J.; DiStefano P. S., Aging and metabolism: drug discovery opportunities. Nature Reviews Drug Discovery 2005, 4, 569-580. 7. Guilherme, A.; Virbasius, J. V.; Puri, V.; Czech, M. P., Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nature Reviews Molecular Cell Biology 2008, 9, 367-377 . 8. National Institutes of Health , What I need to know about Diabetes Medicines, National Institute Diabetes and Digestive and Kidney Dieases, U.S., (2008) 9. Cheng, A. Y. Y.; Fantus, I. G., Oral antihyperglycemic therapy for type 2 diabetes mellitus. Canadian Medical Association Journal 2005, 172, 213-226. 10. Ashiya, M.; Smith, R. E. T., Non-insulin therapies for type 2 diabetes. Nature Reviews Drug Discovery 2007, 6, 777-778. 11. Krentz, A. J.; Patel, M. B.; Bailey, C. J., New drugs for type 2 diabetes mellitus what is their place in therapy? Drugs 2008, 68, 2131-2162. 12. Tan, M. H., α-glucosidase inhibitors in the treatment of diabetes. Current Opinion in Endocrinology and Diabetes 1997, 4, 48-55. 13. Scheen, A. J., Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs 2003, 63, 933-951. 14. Scott, L. J.; Spencer, C. M., Miglitol - A review of its therapeutic potential in type 2 diabetes mellitus. Drugs 2000, 59, 521-549. 15. Puls, W.; Keup, U.; Krause, H. P.; Thomas, G., glucosidase inhibition - new approach to treatment of carbohydrate dependent metabolic disorders. Diabetologia 1977, 13, 426-426. 16. Horii, S.; Fukase, H.; Matsuo, T.; Kameda, Y.; Asano, N.; Masui, K., Synthesis and a-D-glucosidase inhibitory activity of N-substituted valiolamine derivatives as potent oral antidiabetic agents. Journal of medicinal chemistry 1986, 29, 1038-46 17. Matsuo, T.; Odaka, H.; Ikeda, H., effect of an intestinal disaccharidase inhibitor (ao-128) on obesity and diabetes. American Journal of Clinical Nutrition 1992, 55, S314-S317. 18. Satoh, N.; Shimatsu, A.; Yamada, K.; Aizawa-Abe, M.; Suganami, T.; Kuzuya, H.; Ogawa, Y., An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients. Metabolism-Clinical and Experimental 2006, 55, 786-793. 19. Kameda, Y.; Asano, N.; Yamaguchi, T.; Matsui, K., validoxylamines as trehalase inhibitors. Journal of Antibiotics 1987, 40, 563-565. 20. Legler, G.; Finken, M. T.; Felsch, S., Synthesis, from nojirimycin, of N-1-alkyl-D-gluconamidines as potential glucosidase inhibitors. Carbohydrate Research 1996, 292, 91-101. 21. Kimura, T.; Nakagawa, K.; Kubota, H.; Kojima, Y.; Goto, Y.; Yamagishi, K.; Oita, S.; Oikawa, S.; Miyazawa, T., Food-grade mulberry powder enriched with 1-deoxynojirimycin suppresses the elevation of postprandial blood glucose in humans. Journal of Agricultural and Food Chemistry 2007, 55, 5869-5874. 22. Kong, W. H.; Oh, S. H.; Ahn, Y. R.; Kim, K. W.; Kim, J. H.; Seo, S. W., Antiobesity effects and improvement of insulin sensitivity by 1-deoxynojirimycin in animal models. Journal of Agricultural and Food Chemistry 2008, 56, 2613-2619. 23. Aoki, K.; Nakamura, A.; Ito, S.; Nezu, U.; Iwasaki, T.; Takahashi, M.; Kimura, M.; Terauchi, Y., Administration of miglitol until 30 min after the start of a meal is effective in type 2 diabetic patients. Diabetes Research and Clinical Practice 2007, 78, 30-33. 24. Yokoyama, H.; Kannno, S.; Ishimura, I.; Node, K., Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus. Metabolism-Clinical and Experimental 2007, 56, 1458-1463. 25. Fletcher, H. G.; Anderson, L.; Lardy, H. A., the nomenclature of the cyclohexitols and their derivatives. Journal of Organic Chemistry 1951, 16, 1238-1246. 26. Bhat, K. A.; Shah, B. A.; Gupta, K. K.; Pandey, A.; Bani, S.; Taneja, S. C., Semi-synthetic analogs of pinitol as potential inhibitors of TNF-alpha cytokine expression in human neutrophils. Bioorganic & Medicinal Chemistry Letters 2009, 19, 1939-1943. 27. Kim, M. J.; Yoo, K. H.; Kim, J. H.; Seo, Y. T.; Ha, B. W.; Kho, J. H.; Shin, Y. G.; Chung, C. H., Effect of pinitol on glucose metabolism and adipocytokines in uncontrolled type 2 diabetes. Diabetes Research and Clinical Practice 2007, 77, S247-S251. 28. Davis, A.; Christiansen, M.; Horowitz, J. F.; Klein, S.; Hellerstein, M. K.; Ostlund, R. E., Effect of pinitol treatment on insulin action in subjects with insulin resistance. Diabetes Care 2000, 23, 1000-1005. 29. Fonteles, M. C.; Huang, L. C.; Larner, J., Infusion of pH 2.0 D-chiro-inositol glycan insulin putative mediator normalizes plasma glucose in streptozotocin diabetic rats at a dose equivalent to insulin without inducing hypoglycaemia. Diabetologia 1996, 39, 731-734. 30. Bates, S. H.; Jones, R. B.; Bailey, C. J., Insulin-like effect of pinitol. British Journal of Pharmacology 2000, 130, 1944-1948. 31. Gecthan, P.; Prince, P. S. M., Antihyperlipidemic effect of D-pinitol on streptozotocin-induced diabetic Wistar rats. Journal of Biochemical and Molecular Toxicology 2008, 22, 220-224. 32. Sivakumar, S.; Subramanian, S. P., Pancreatic tissue protective nature of D-Pinitol studied in streptozotocin-mediated oxidative stress in experimental diabetic rats. European Journal of Pharmacology 2009, 622, 65-70. 33. Herz, W., The Biology and Chemistry of the Compositae. Academic Press, New York. 1, 1977, 337-357 34. Rodriguez, E.; Towers, G. H. N.; Mitchell, J. C., Biological-activities of sesquiterpene lactones. Phytochemistry 1976, 15, 1573-1580. 35. Picman, A. K., Biological-activities of sesquiterpene lactones. Biochemical Systematics and Ecology 1986, 14, 255-281. 36. Pillay, P., University of Pretoria faculty of natural & agricultural sciences master thesis: Structure elucidation of antiplasmodial sesquiterpene lactones from Vernonia staehelinoides and Oncosiphon piluliferum. 2005, December 37. Kupchan, S. M.; Fessler, D. C.; Eakin, M. A.; Giacobbe, T. J., reactions of alpha methylene lactone tumor inhibitors with model biological nucleophiles. Science 1970, 168, 376. 38. Schmidt, T. J., Helenanolide-type sesquiterpene lactones .3. Rates and stereochemistry in the reaction of helenalin and related helenanolides with sulfhydryl containing biomolecules. Bioorganic & Medicinal Chemistry 1997, 5, 645-653. 39. Dirsch, V. M.; Stuppner, H.; Vollmar, A. M. Helenalin triggers a CD95 death receptor-independent apoptosis that is not affected by overexpression of bcl-xl or bcl-21 Cancer Research 2001, 61, 5817. 40. Brunn., G.; Fauq., A. H. ; Chow., S. ; Kozikowski., A. P.; Gallegos ., A.; Powis., G., Cellular pharmacology of D-3-azido-3-deoxy-myo-inositoi,an inhibitor of phosphatidylinositol signaling having antiproliferative activity. Cancer Chemotherapy and pharmacology 1994, 35, 71-79 41. Lillelund, V. H.; Jensen, H. H.; Liang, X. F.; Bols, M., Recent developments of transition-state analogue glycosidase inhibitors of non-natural product origin. Chemical Reviews 2002, 102, 515-553. 42. Berecibar, A.; Grandjean, C.; Siriwardena, A., Synthesis and biological activity of natural aminocyclopentitol glycosidase inhibitors: Mannostatins, trehazolin, allosamidins, and their analogues. Chemical Reviews 1999, 99, 779-844. 43. Sureshan, K. M.; Ikeda, K.; Asano, N.; Watanabe, Y., Efficient routes to optically active azido-, amino-, di-azido- and di-amino-cyclitols with chiro- and allo-configuration from myo-inositol. Tetrahedron Letters 2004, 45, 8367-8370. 44. Chaubal, R.; Pawar, P. V.; Hebbalkar, G. D.; Tungikar, V. B.; Puranik, V. G.; Deshpande, V. H.; Deshpande, N. R., Larvicidal activity of Acacia nilotica extracts and isolation of D-pinitol - A bioactive carbohydrate. Chemistry & Biodiversity 2005, 2, 684-688. 45. Kozikowski, A.P., Fauq, A.H., Wilcox, R.A. & Nahorski, S.R., Tools for cell signaling: synthesis of the 3-phosphatase-resistant 1,3,4,5-InsP4 mimic, 1D-myo-inositol 1,4,5-trisphosphate 3-phosphorothioate. Journal of Organic Chemistry 1994, 59, 2279-2281. 46. Kozikowski, A. P.; Ognyanov, V. I.; Fauq, A. H.; Nahorski, S. R.; Wilcox, R. A., Synthesis of 1d-3-deoxy-myo-inositol, 1d-2,3-dideoxy-myo-inositol, and 1d-2,3,6-trideoxy-myo-inositol 1,4,5-trisphosphate from quebrachitol, their binding affinities, and calcium-release activity. Journal of the American Chemical Society 1993, 115, 4429-4434. 47. Herr, C. H.; Whitmore, F. C.; Schiessler, R. W., The wolff-kishner reaction at atmospheric pressure. Journal of the American Chemical Society 1945, 67, 2061-2063. 48. Srikrishna, A.; Vijaykumar, D., A formal total synthesis of (+/-)-alpha-pinguisene and (+/-)-pinguisenol. Journal of the Chemical Society-Perkin Transactions 1 1999, 10, 1265-1271. 49. Abad, A.; Agullo, C.; Arno, M.; Marin, M. L.; Zaragoza, R. J., First diastereoselective synthesis of (-)-thyrsiflorin A methyl ester. Synlett 1997, 5, 574-576. 50. http://www.organic-chemistry.org/namedreactions/wolff-kishner-reduction.shtm 51. Pine, S. H.; Sanchez, B. L., Formic acid-formaldehyde methylation of amines. Journal of Organic Chemistry 1971, 36, 829-832 52. Farkas, E.; Sunman, C. J., Chiral synthesis of doxpicomine. Journal of Organic Chemistry 1985, 50, 1110-1112. 53. http://en.wikipedia.org/wiki/Eschweiler-Clarke_reaction 54. Comprehensive Organic Functional Group Transformation 2, 2nd p30, Katritazk, A., Taylor, R., USA (1995) 55. Salvatore, R. N.; Yoon, C. H.; Jung, K. W., Synthesis of secondary amines. Tetrahedron 2001, 57, 7785-7811. 56. Salvatore, R. N.; Nagle, A. S.; Jung, K. W., Cesium effect: High chemoselectivity in direct N-alkylation of amines. Journal of Organic Chemistry 2002, 67, 674-683. 57. Galli, C., Cesium ion effect and macrocyclization - a critical-review. Organic Preparations and Procedures International 1992, 24, 285-287. 58. Blum, Z., The ‘Caesium Effect’ Revisited. Acta Cheimca Scandinavica 1989, 43, 248-250. 59. AbdelMagid, A. F.; Carson, K. G.; Harris, B. D.; Maryanoff, C. A.; Shah, R. D., Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures. Journal of Organic Chemistry 1996, 61, 3849-3862. 60. Lillelund, V. H.; Jensen, H. H.; Liang, X.; Bols, M., Recent developments of transition state analogue glycosidase inhibitors of non-natural product origin. Chemical Reviews, 2002, 102, 515-553. 61. 謝伯鴻, 國立台灣大學醫學院藥學研究所碩士論文:苯丙醯黃酮屬裡糖苷類化合物之製備作抑制甲型葡萄糖水解酶之研究. 2008, July 62. Herz, W.; Kagan, H. B., Determination of the absolute configuration of hydroxylated sesquiterpene lactones by horeau's method of asymmetric esterification. Journal of Organic Chemistry 1967, 32, 216–218. 63. Devivar, A. R.; Rodrigue.L; Romo, J.; Lakshmik.Mv; Mirringt.Rn; Kagan, J.; Herz, W., Constituents of helenium species .19. further transformations of helenalin and its congeners . 1-epihelenalin and 1-epiambrosin series. Tetrahedron 1966, 22, 3279-3292. 64. Pistia-Brueggeman, G. & Hollingsworth, R.I. A preparation and screening strategy for glycosidase inhibitors. Tetrahedron 2001, 57, 8773-8778. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/22467 | - |
| dc.description.abstract | 21世紀，隨著環境及生活習性的改變，「三高」成了現代人的文明病，其中的高血糖則是和糖尿病 (Diabetes Mellitus) 息息相關，已成為世界各地廣泛盛行的一種慢性病，使用藥物治療對於糖尿病達到理想血糖控制是必要的，雖然目前市面上已有多種口服降血糖用藥可供選擇，但都有其相對的禁忌及副作用，因此新藥的開發仍有相當需求。
α-glucosidase inhibitor (AGH) 藥物的作用機轉為抑制在小腸刷狀緣上的甲型葡萄糖水解酶，進而減少碳水化合物的代謝，而減少葡萄糖之產生與吸收，可改善飯後高血糖的情形。根據文獻報導，松醇 (D-pinitol) 具有擬胰島素作用而可增加細胞對葡萄糖的吸收，本實驗設計，即希望以松醇為起始物進行結構修飾，得到類似Miglitol或是Voglibose架構之化合物並測試其活性，首先將松醇第四位置之羥基經四步反應轉換為胺基，接著在氮上進行不同的醯烷化反應，所得產物大致可分成三個系列，(1) 直接性的烷基化 (化合物23~26) (2) 醯化反應 (化合物27~30) (3) 還原性胺化反應 (化合物 31~34)，將所得化合物進行甲型葡萄糖水解酶活性測試，結果抑制活性皆不佳，將進行後續相關之glucose transporter assay。 本實驗之另一部分為利用化學反應方法改善分離之不便，由鵝不食草中分離出的主要成分之主架構為倍半萜環酯類 (sesquiterpene lactones) 中的pseudoguaianolide，被認為具有細胞毒殺性，而在支鏈上有不同的碳數取代，也因結構的極性相似度高造成分離上的繁瑣及困難，利用水解方式切除酯鍵保留原主架構，以供後續相關的衍生化產物之製備。 | zh_TW |
| dc.description.abstract | The prevalence of type 2 diabetes continues to grow worldwide. The use of drug therapy to help people who suffer this disease to control their blood glucose is necessary. Despite the availability of several classes of anti-diabetic drugs, maintaining sufficient long-term glycaemic control remains a common challenge, and side effects have also become an increasingly important issue. Therefore, the development of new anti-diabetic drug is urgent.
The mechanism of α-glucosidase inhibitor (AGH) is targeting on the enzymes in the small intestine brush border, which are responsible for breakdown of oligosaccharides and disaccharides into monosaccharides suitable for absorption. They can delay the digestion of carbohydrates and therefore retard glucose entry into the systemic circulation, and then lower postprandial glucose levels to achieve therapeutic control of diabetes. Recent research has found D-pinitol may have profound insulin-like properties and is proven to be an excellent aid in improving glucose metabolism. In this study, D-pinitol was used as starting material to prepare azapinitols, like Miglitol or Voglibose, whose activity were assayed. Through four step reactions, was converted hydroxyl group at C-4 in pinitol to an amine group. Subsequent, N-acylation and N-alkylation yielded three series of products: (1) acylation (compound 23~26) (2) reductive amination (compound 27~30) (3) direct alkylation (compound 31~34). Collect all of the synthesize compounds to test the α-glucosidase assay. The second part of this thesis attempted to solve the separation problem of pseudoguaianolide present in Centipeda minima by chemical method. The structures of this series of compounds only different in the carbon numbers on the ester side chain. The greatly similar polarity causes difficulty for further purification. Thus, we tried to use hydrolyze the various ester side chain to form the same product containing 6-hydroxy group for further structure modification. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-08T04:18:28Z (GMT). No. of bitstreams: 1 ntu-99-R97423002-1.pdf: 7787423 bytes, checksum: 60d88d64899c2eb1665cf12718080d92 (MD5) Previous issue date: 2010 | en |
| dc.description.tableofcontents | 摘 要 iii
Abstract iv 表目錄 (List of Tables) x 流程目錄 (List of Schemes) xi 圖及光譜圖目錄 (List of Figures and Spestra Appendices) xii 詞 彙 (Glossary) xx 第一章 序論 1 1.1 糖尿病簡介 1 1.1. 1 糖尿病 1 1.1. 2 糖尿病致病機轉 2 1. 2 糖尿病治療藥物 4 1.2. 1 臨床上使用中之甲型葡萄糖水解酶抑制劑 (α-glucosidase inhibitors) 6 1. 3 D-Pinitol 8 1. 4 倍半萜環酯類 (sesquiterpene lactones) 10 1. 5 研究目的 11 1.5. 1 D-Pinitol之結構修飾研究 11 1.5. 2 Pseudoguaianolide類水解研究 12 第二章 實驗結果與討論 13 2. 1 松醇之結構修飾研究 13 2.1. 1 Pinitol diacetonide (2) 之製備 13 2.1. 2 4β-Amino-4-dehydroxypinitol diacetonide (7) 之製備 14 2.1. 3 4β-N,N-Dimethyl-4-dehydroxypinitol diacetonide (8) 之製備 17 2.1. 4 化合物9~12之製備 18 2.1. 5 化合物13~16之製備 20 2.1. 6 化合物17~20之製備 21 2.1. 7 化合物21 ~ 30之製備 23 2.1. 8 藥物活性測試 26 2.1.8. 1 甲型葡萄糖水解酶之活性試驗結果 26 2. 2 Pseudoguaianolide水解反應研究 29 2.2. 1 化合物40之製備 29 2.2. 2 酸水解條件之最適化探討 31 2.2. 3 鹼水解條件之最適化 36 2.2.3. 1 氫氧化鈉鹼水解 36 2.2.3. 2 碳酸鉀與相轉移催化劑反應 38 2.2. 4 還原性酯基切割 39 第三章 實驗方法 42 3. 1 儀器與材料 42 3.1. 1 理化性質測定儀器 42 3.1. 2 成分分離之儀器及材料 42 3.1. 3 試劑、材料及溶劑 43 3. 2 4β-Amino-4-dehydroxypinitol (7) 之製備 44 3.2. 1 Pinitol diacetonide (2) 之製備 44 3.2. 2 4,4-Didehydropinitol diacetonide (3) 之製備 45 3.2. 3 4α-Methanesulfonyl-4-dehydroxypinitol diacetonide (4) 之製備 45 3.2. 4 4β-Azido-4-dehydroxypinitol diacetonide (6) 之製備 46 3.2. 5 4β-Amino-4-dehydroxypinitol diacetonide (7) 之製備 47 3. 3 4β-N,N-Dimethyl-4-dehydroxypinitol diacetonide (8) 之製備 48 3.3. 1 4β-N,N-Dimethyl-4-dehydroxypinitol diacetonide (8) 之製備 48 3. 4 化合物9~12之製備 49 3.4. 1 4β-N-Ethyl-4-dehydroxypinitol diacetonide (9) 及4β-N,N-Diethyl-4-dehydroxypinitol diacetonide (10) 之製備 49 3.4. 2 4β-N-Allyl-4-dehydroxypinitol diacetonide (11) 及4β-N,N-Diallyl-4-dehydroxypinitol diacetonide (12) 之製備 51 3. 5 化合物13~16之製備 52 3.5. 1 4β-N-Acetyl-4-dehydroxypinitol diacetonide (13) 之製備 52 3.5. 2 4β-N-Propionamido-4-dehydroxypinitol diacetonide (14) 之製備 53 3.5. 3 4β-N-Butyramido-4-dehydroxypinitol diacetonide (15) 之製備 54 3.5. 4 4β-N-Isobutyramido-4-dehydroxypinitol diacetonide (16) 之製備 55 3. 6 化合物17~20之製備 56 3.6. 1 4β-N-Benzyl-4-dehydroxypinitol diacetonide (17) 之製備 56 3.6. 2 4β-N-Propyl-4-dehydroxypinitol diacetonide (18) 之製備 57 3.6. 3 4β-N-Butyl-4-dehydroxypinitol diacetonide (19) 之製備 58 3.6. 4 4β-N-Isobutyl-4-dehydroxypinitol diacetonide (20) 之製備 59 3. 7 化合物21~34之製備 60 3.7. 1 4β-Amino-4-dehydroxypinitol (21) 之製備 60 3.7. 2 4β-N,N-Dimethyl–4-dehydroxypinitol (22) 之製備 61 3.7. 3 4β-N-Ethyl-4-dehydroxypinitol (23) 之製備 62 3.7. 4 4β-N,N-Diethyl-4-dehydroxypinitol (24) 之製備 63 3.7. 5 4β-N-Allyl-4-dehydroxypinitol (25) 之製備 63 3.7. 6 4β-N,N-Diallyl-4-dehydroxypinitol (26) 之製備 64 3.7. 7 4β-N-Acetyl-4-dehydroxypinitol (27) 之製備 65 3.7. 8 4β-N-Propionamido-4-dehydroxypinitol (28) 之製備 66 3.7. 9 4β-N-Butyramido-4-dehydroxypinitol (29) 之製備 67 3.7. 10 4β-N-Isobutyramido-4-dehydroxypinitol (30) 之製備 68 3.7. 11 4β-N-Benzyl-4-dehydroxypinitol (31) 之製備 69 3.7. 12 4β-N-Propyl-4-dehydroxypinitol (32) 之製備 70 3.7. 13 4β-N-Butyl-4-dehydroxypinitol (33) 之製備 70 3.7. 14 4β-N-Isobutyl-4-dehydroxypinitol (34) 之製備 71 3. 8 甲型葡萄糖水解酶之活性試驗(α-Glucosidase assay) 72 3.8. 1 原理 72 3.8. 2 實驗方法 73 3.8.2. 1 試劑配製 73 3.8.2. 2 實驗步驟 73 3. 9 化合物40、42、43~47之製備 74 3.9. 1 化合物40之製備 74 3.9. 2 化合物42之製備 75 3.9. 3 Tetrahydrohelenalin (43)、Tetrahydro-1-epi-allohelenalin (44)、Dihydro-1-epi-allohelenalin (45) 以鹽酸之製備 76 3.9. 4 Dihydromexicanin (46)以氫氧化鈉之製備 78 3.9. 5 Dihydromexicanin (46)、(47)以硼酸氫鈉之製備 79 3.9. 6 Tetrahydrohelenalin (43) 、Tetrahydro-1-epi-allohelenalin (44)、Dihydromexicanin (46) 以碳酸鉀之製備 80 參考文獻 82 附 圖 (Spectra Appendices) 89 | |
| dc.language.iso | zh-TW | |
| dc.title | 松醇及pseudoguaianolide衍生物之製備 | zh_TW |
| dc.title | Preparation of aminopinitol and pseudoguaianolide derivatives | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 98-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 李安榮,陳繼明 | |
| dc.subject.keyword | 糖尿病,甲型葡萄糖水解酶,抑制劑,松醇,倍半萜,環酯類,細胞毒殺性,含胺松醇衍生物, | zh_TW |
| dc.subject.keyword | Diabetes mellitus,α-glucosidase inhibitor,D-Pinitol,Sesquiterpene lactones,pseudoguaianolide,cytotoxicity,amino-pinitol derivatives, | en |
| dc.relation.page | 199 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2010-07-27 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 藥學研究所 | zh_TW |
| 顯示於系所單位： | 藥學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-99-1.pdf 目前未授權公開取用 | 7.6 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。